AR and pachyonychia congenita: Surprisingly, the novel AR antagonist MDV3100 targeting the LBD of the ARfl and currently in clinical trials for CRPC [21], [22] were found to inhibit castration-resistant growth induced by the expression of constitutive AR-V7 in an animal model for PC [17].